Industry news

Pfizer makes offer for AstraZeneca

Read time: 1 mins

Last updated:21st Apr 2014

Published:21st Apr 2014

Source: Pharmawand

It is reported that Pfizer has offered �60 billion for AstraZeneca but that the approach was rejected. The aim of Pfizer could be to secure access to immunotherapies for cancer treatment in development at Astra Zeneca and make cost savings. A second approach is likely. An attraction to Pfizer is to find a home for its offshore US dollars in an acquisition as repatriation of the funds will attract US tax.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Industry news

Xoma Corporation announces completion of acquisition of shares of Kinnate Biopharma Inc.

XOMA Corporation, a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health

1 mins

Industry news

Regeneron Pharma and Mammoth Biosciences collaborate on CRISPR based gene editing therapies.

Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types

1 min

Industry news

Antibe Therapeutics has receiver appointed.

Antibe Therapeutics Inc. announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) was heard before the Ontario Superior Court of Justice (Commercial List) (the “Court”) on April 18, 2024 and the decision was reserved

1 min

See all news